Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare? [electronic resource]
Producer: 20081211Description: 606-7 p. digitalISSN:- 1743-4300
- Adrenergic beta-Antagonists -- economics
- Aged
- Angiotensin II Type 1 Receptor Blockers -- economics
- Angiotensin-Converting Enzyme Inhibitors -- economics
- Aspirin -- economics
- Cardiovascular Agents -- economics
- Computer Simulation
- Cost Savings
- Cost-Benefit Analysis
- Drug Costs
- Drug Therapy, Combination
- Humans
- Hypolipidemic Agents -- economics
- Insurance, Pharmaceutical Services -- economics
- Medicare -- economics
- Models, Economic
- Myocardial Infarction -- drug therapy
- Patient Compliance
- Quality-Adjusted Life Years
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.